10%
CALCIUM CHLORIDE
Injection, USP
100 mg/mL
Rx only
Represents 27 mg (1.4 mEq) Ca++/mL
ABBOJECT® Syringe
A HYPERTONIC SOLUTION IN A 10 ML
UNIT OF USE SYRINGE FOR PROMPT
INTRAVENOUS INJECTION.
CAUTION: This solution must not be injected
intramuscularly or subcutaneously.

DESCRIPTION
10% Calcium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution containing
100 mg (1.4 mEq/mL) of calcium chloride, dihydrate (1.4 mEq each of Ca++ and Cl–) in water for
injection. It is provided in a 10 mL Unit of Use Syringe to facilitate prompt intravenous injection.
The solution is administered only by intravenous or intraventricular cavity injection as a calcium
replenisher.

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only
for use as a single-dose injection. As per USP testing, when diluted with water for injection to
make a 5% solution, the pH of calcium chloride injection is 6.3 (5.5 to 7.5). May contain
hydrochloric acid and/or sodium hydroxide for pH adjustment. The osmolar concentration is
2.04 mOsmol/mL (calc.). 10% Calcium Chloride Injection, USP is oxygen sensitive.

Calcium Chloride, USP dihydrate is chemically designated CaCl2 ∙ 2H2O (dihydrate) white,
odorless fragments or granules freely soluble in water.

CLINICAL PHARMACOLOGY
Calcium is the fifth most abundant element in the body and the major fraction is in the bony
structure. Calcium plays important physiological roles, many of which are poorly understood. It is
essential for the functional integrity of the nervous and muscular systems. It is necessary for normal
cardiac function and is one of the factors that operates in the mechanisms involved in the
coagulation of blood.

Calcium chloride in water dissociates to provide calcium (Ca++) and chloride (Cl–) ions. They
are normal constituents of the body fluids and are dependent on various physiological mechanisms
for maintenance of balance between intake and output. Approximately 80% of body calcium is
excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

INDICATIONS AND USAGE
10% Calcium Chloride Injection, USP is indicated (1) for the treatment of hypocalcemia in those
conditions requiring a prompt increase in blood plasma calcium levels, (2) in the treatment of
magnesium intoxication due to overdosage of magnesium sulfate and (3) to combat the deleterious
effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the
increased potassium level in the extracellular fluid.

10% Calcium Chloride Injection, USP also may be used in cardiac resuscitation when weak or
inadequate contractions return following defibrillation or when epinephrine injection has failed to
strengthen myocardial contractions.
CONTRAINDICATIONS
Calcium chloride is contraindicated for cardiac resuscitation in the presence of ventricular fibrillation or in patients with the risk of existing digitalis toxicity.

WARNINGS
10% Calcium Chloride Injection, USP is irritating to veins and must not be injected into tissues, since severe necrosis and sloughing may occur. Great care should be taken to avoid extravasation or accidental injection into perivascular tissues.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS
Do not administer unless solution is clear and seal is intact. Discard unused portion.

Because of its additive effect, calcium should be administered very cautiously to a patient who is digitalized or who is taking effective doses of digitalis or digitalis-like preparations.

Injections should be made slowly through a small needle into a large vein to minimize venous irritation and avoid undesirable reactions. It is particularly important to prevent a high concentration of calcium from reaching the heart because of the danger of cardiac syncope. If injected into the ventricular cavity in cardiac resuscitation, it must not be injected into the myocardial tissue.

Pregnancy Category C. Animal reproduction studies have not been conducted with calcium chloride. It also is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Calcium chloride should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS
Rapid injection may cause the patient to complain of tingling sensations, a calcium taste, a sense of oppression or “heat wave”.

Injections of calcium chloride are accompanied by peripheral vasodilatation as well as a local “burning” sensation and there may be a moderate fall in blood pressure.

Should perivascular infiltration occur, I.V. administration at that site should be discontinued at once. Local infiltration of the affected area with 1% procaine hydrochloride, to which hyaluronidase may be added, will often reduce venouspasm and dilute the calcium remaining in the tissues locally. Local application of heat may also be helpful.

DRUG ABUSE AND DEPENDENCE
None known.

OVERDOSAGE
Too rapid injection may produce lowering of blood pressure and cardiac syncope. Persistent hypercalcemia from overdosage of calcium is unlikely because of rapid excretion. In the event of untoward effects from excessive calcium administration, the drug should be discontinued promptly, the patient re-evaluated and appropriate countermeasures instituted, if necessary. See PRECAUTIONS and ADVERSE REACTIONS.
DOSAGE AND ADMINISTRATION

10% Calcium Chloride Injection, USP is administered only by slow intravenous injection (not to exceed 1 mL/min) and/or in cardiac resuscitation, by injection into the ventricular cavity. It must not be injected into the myocardium.

The usual precautions for intravenous therapy should be observed. If time permits, the solution should be warmed to body temperature. The injection should be halted if the patient complains of any discomfort; it may be resumed when symptoms disappear. Following injection, the patient should remain recumbent for a short time.

The usual adult dosage in hypocalcemic disorders ranges from 500 mg to 1 g (5 to 10 mL) at intervals of 1 to 3 days, depending on the response of the patient and/or results of serum calcium determinations. Repeated injections may be required because of rapid excretion of calcium.

In magnesium intoxication, an initial adult dose of 500 mg (5 mL) should be administered promptly and the patient observed for signs of recovery before further doses are given.

In hyperkalemic ECG disturbances of cardiac function, the dosage of calcium chloride injection should be titrated by constant monitoring of ECG changes during administration.

In cardiac resuscitation, the usual adult dosage ranges from 500 mg to 1 g (5 to 10 mL) intravenously, or from 200 to 800 mg (2 to 8 mL) when injected into the ventricular cavity.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

To prevent needle-stick injuries, needles should not be recapped, purposely bent or broken by hand.

HOW SUPPLIED

10% Calcium Chloride Injection, USP is supplied in single-dose containers as follows:

<table>
<thead>
<tr>
<th>List No.</th>
<th>Container</th>
<th>Size</th>
<th>Needle</th>
</tr>
</thead>
<tbody>
<tr>
<td>4928</td>
<td>Abboject® Unit of Use Syringe with male Luer lock adapter and protected needle</td>
<td>10 mL</td>
<td>20-G</td>
</tr>
</tbody>
</table>

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Revised: October, 2004

Abboject® is a trademark of the Abbott group of companies

©Hospira 2004 EN-0551 Printed in USA

HOSPIRA, INC., LAKE FOREST, IL 60045 USA